Stephen A. Trowbridge, Executive Vice President and CFO of AngioDynamics Inc., filed a Form 4 on October 30, 2026, disclosing the sale of a combined 25,335 shares of common stock across two transactions on October 28 and October 29, 2026.

Key Highlights

  • First sale: 1,720 shares of common stock were disposed of on October 28, 2026, at a weighted average price of $12.17 per share, with individual transaction prices ranging from $12.15 to $12.20.
  • Second sale: 23,615 shares were disposed of on October 29, 2026, at a weighted average price of $12.27 per share, with individual transaction prices ranging from $12.07 to $12.35.
  • Remaining ownership: Following both transactions, Trowbridge directly held 280,461 shares of common stock, according to the filing.
  • Transaction code: Both transactions were coded "S" (open-market sale) under Instruction 8 of the form.
  • Reporting person role: Trowbridge is identified in the filing as EVP and CFO of AngioDynamics Inc. (NASDAQ:ANGO).

Trowbridge CFO Share Sales at AngioDynamics: October 28-29, 2026

According to the Form 4 filed with the U.S. Securities and Exchange Commission on October 30, 2026, Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer of AngioDynamics Inc. (NASDAQ:ANGO), reported two separate dispositions of common stock in consecutive trading sessions. The filing lists both transactions under Table I as direct ownership disposals coded "S," indicating open-market sales.

On October 28, 2026, the filing discloses that Trowbridge disposed of 1,720 shares at a weighted average price of $12.17, with the filing noting that individual transactions occurred at prices ranging from $12.15 to $12.20 inclusive. Following that sale, his directly held position stood at 304,076 shares. On October 29, 2026, an additional 23,615 shares were sold at a weighted average price of $12.27, with prices across individual transactions ranging from $12.07 to $12.35 inclusive, reducing his direct beneficial ownership to 280,461 shares.

The filing notes that the weighted average prices are footnoted and that Trowbridge "has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price" within each stated range. The form was signed by Lawrence T. Weiss as Attorney in Fact on October 30, 2026. No derivative securities transactions were reported.

What Was Disclosed

The filing reports two open-market sales of AngioDynamics common stock by CFO Stephen A. Trowbridge totaling 25,335 shares on October 28 and 29, 2026, at weighted average prices of $12.17 and $12.27, leaving him with a direct beneficial ownership of 280,461 shares.